VIR250117P22500
- 0.00
- 0.000.00%
Vir Biotechnology Newsroom
Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20
Morgan Stanley Upgrades Vir Biotechnology(VIR.US) to Buy Rating, Raises Target Price to $20
Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $26
H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $110
Vir Biotechnology: Buy Rating Supported by Promising TCE Programs and Strategic Partnerships
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $14 to $28
Vir Biotechnology Is Maintained at Neutral by JP Morgan
Vir Biotechnology Analyst Ratings
Morgan Stanley Upgrades Vir Biotechnology to Overweight From Equalweight, Adjusts Price Target to $20 From $10
Vir Biotechnology (VIR) Gets a Buy From Barclays
Vir Biotechnology's Early Stage Developments and Valuation Lead to Hold Rating Amid Long-Term Promise and Near-Term Uncertainties
Vir Biotechnology's Early Promise in Clinical Trials Warrants Hold Rating Amid Uncertainties
Vir Biotechnology's Promising TCE Oncology Assets Earn Buy Rating From Joseph Stringer
BofA Securities Maintains Vir Biotechnology(VIR.US) With Hold Rating, Cuts Target Price to $14
Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Hold Rating, Maintains Target Price $10
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), PTC Therapeutics (PTCT) and Vir Biotechnology (VIR)
J.P. Morgan Sticks to Their Hold Rating for Vir Biotechnology (VIR)
Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target